Companies › GE Healthcare
6 active drug programs in 8 registered trials: 4 Phase 2, 3 Phase 4, 1 Phase 1; Oncology, Other, Cardiovascular, Hematology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| 18F Fluoroestradiol (ESTROTEP) Estrogen receptor imaging agent | ESR1 | Phase 4 | Metastatic Breast Cancer | – |
| Sonazoid™ Ultrasound contrast agent | – | Phase 4 | Focal Liver Lesions | – |
| GE-287 Amyloid PET imaging agent (F-18 labeled) | – | Phase 2 | Cognitive Dysfunction | Feb 2027 |
| Mangaciclanol (GEH200486 Injection) Magnetic resonance imaging contrast agent | – | Phase 2 | Known or Highly Suspected Central Nervous System (CNS) Lesion | Nov 2027 |
| GEH300079 (68Ga) Injection 68Ga-labeled imaging agent for PET/CT detection of peritoneal carcinomatosis | – | Phase 2 | Colorectal Cancer | Jun 2029 |
| Regadenoson Adenosine A2a receptor agonist | ADORA2A | Phase 1 | Myocardial Ischemia; Heart Transplant Failure and Rejection; Sickle Cell Disease | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05486182 | 18F Fluoroestradiol (ESTROTEP) | Phase 4 | Metastatic Breast Cancer | Oncology | Apr 2025 |
| NCT06639828 | Sonazoid™ | Phase 4 | Focal Liver Lesions | Oncology | Jul 2026 |
| NCT04604782 | Regadenoson | Phase 1 | Myocardial Ischemia | Cardiovascular | Dec 2026 |
| NCT03102125 | Regadenoson | Phase 4 | Heart Transplant Failure and Rejection | Other | Jan 2027 |
| NCT07873463 | GE-287 | Phase 2 | Cognitive Dysfunction | Neurology | Feb 2027 |
| NCT05583721 | Regadenoson | Phase 2 | Sickle Cell Disease | Hematology | Sep 2027 |
| NCT07472491 | Mangaciclanol (GEH200486 Injection) | Phase 2 | Known or Highly Suspected Central Nervous System (CNS) Lesion | Other | Nov 2027 |
| NCT07219238 | GEH300079 (68Ga) Injection | Phase 2 | Colorectal Cancer | Oncology | Jun 2029 |
Shanghai Best-Link Bioscience Shanghai Kechow Pharma Atossa Therapeutics Guangzhou Lupeng Pharmaceutical Company Stemline Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.